Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

FRIDAY, May 16, 2025 (HealthDay News) — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to ...

"The Novo Nordisk Foundation is increasing its influence and has appointed its chairman, Lars Rebien Sørensen, as an observer ...

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

Novo Nordisk A/S announced earlier today that Lars Rebien Sørensen, Chair of the Novo Nordisk Foundation, will join its board of directors, initially as an observer. In the same announcement, Novo ...

Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price ...

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...